Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Net Cash Flow (2016 - 2025)

Avalo Therapeutics' Net Cash Flow history spans 12 years, with the latest figure at -$11.2 million for Q4 2025.

  • For Q4 2025, Net Cash Flow fell 121.27% year-over-year to -$11.2 million; the TTM value through Dec 2025 reached -$118.6 million, down 193.3%, while the annual FY2025 figure was -$118.6 million, 193.3% down from the prior year.
  • Net Cash Flow reached -$11.2 million in Q4 2025 per AVTX's latest filing, up from -$15.3 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $102.8 million in Q1 2024 to a low of -$82.7 million in Q2 2025.
  • Average Net Cash Flow over 5 years is -$152150.0, with a median of -$6.7 million recorded in 2022.
  • Peak YoY movement for Net Cash Flow: crashed 1444.51% in 2022, then soared 2784.25% in 2024.
  • A 5-year view of Net Cash Flow shows it stood at -$17.0 million in 2021, then soared by 77.35% to -$3.9 million in 2022, then increased by 28.33% to -$2.8 million in 2023, then skyrocketed by 2004.7% to $52.7 million in 2024, then crashed by 121.27% to -$11.2 million in 2025.
  • Per Business Quant, the three most recent readings for AVTX's Net Cash Flow are -$11.2 million (Q4 2025), -$15.3 million (Q3 2025), and -$82.7 million (Q2 2025).